Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-777-1760
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableOptionable
Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio Inc (NASDAQ:SPHS) announced its quarterly earnings data on Tuesday, August, 14th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.05. View Sophiris Bio's Earnings History.
When is Sophiris Bio's next earnings date?
What price target have analysts set for SPHS?
3 brokers have issued 12 month target prices for Sophiris Bio's stock. Their predictions range from $3.50 to $6.00. On average, they expect Sophiris Bio's stock price to reach $4.8333 in the next twelve months. This suggests a possible upside of 331.5% from the stock's current price. View Analyst Price Targets for Sophiris Bio.
What is the consensus analysts' recommendation for Sophiris Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.
What are Wall Street analysts saying about Sophiris Bio stock?
Here are some recent quotes from research analysts about Sophiris Bio stock:
- 1. Maxim Group analysts commented, "Sophiris’ phase 2B study of topsalysin in localized prostate cancer is approaching its next key data point, effects of a second administration, expected in the next few weeks." (12/6/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Sophiris Bio Inc." (9/13/2018)
Has Sophiris Bio been receiving favorable news coverage?
Media headlines about SPHS stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sophiris Bio earned a news impact score of 1.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Eton Pharmaceuticals (ETON), Sol Gel Technologies (SLGL), Unum Therapeutics (UMRX), Syndax Pharmaceuticals (SNDX), XOMA (XOMA), Corvus Pharmaceuticals (CRVS), DURECT (DRRX), Imprimis Pharmaceuticals (IMMY), OASMIA PHARMACE/ADR (OASM), Catalyst Biosciences (CBIO), Zafgen (ZFGN), Fortress Biotech (FBIO), Mustang Bio (MBIO), Adamis Pharmaceuticals (ADMP) and Checkpoint Therapeutics (CKPT).
What other stocks do shareholders of Sophiris Bio own?
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the folowing people:
- Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)
- Mr. Randall E. Woods, CEO, Pres & Director (Age 67)
- Mr. Peter T. Slover, Chief Financial Officer (Age 44)
- Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)
- Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board
Who are Sophiris Bio's major shareholders?
Sophiris Bio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.81%), Geode Capital Management LLC (0.81%), Hikari Power Ltd (0.67%) and Virtu Financial LLC (0.12%). View Institutional Ownership Trends for Sophiris Bio.
Which institutional investors are buying Sophiris Bio stock?
SPHS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Geode Capital Management LLC, Geode Capital Management LLC and Hikari Power Ltd. View Insider Buying and Selling for Sophiris Bio.
How do I buy shares of Sophiris Bio?
Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of SPHS stock can currently be purchased for approximately $1.12.
How big of a company is Sophiris Bio?
Sophiris Bio has a market capitalization of $33.84 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.
What is Sophiris Bio's official website?
How can I contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]
MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
